First Phase II Rectal Microbicide Study Launched

October 2, 2013

The Microbicide Trials Network launched MTN-017, a Phase II clinical trial of a potential rectal microbicide. The trial, funded by the U.S. National Institutes of Health (NIH), is testing the rectal use of a reduced glycerin gel formulation of the antiretroviral drug tenofovir.  The study products are being provided by Gilead Sciences, Inc., of Foster City, Calif., and by CONRAD.  To read the full press release by MTN, please click here.

1911 North Fort Myer Drive, Suite 900, Arlington, Virginia 22209   T: (703) 524-4744 |